Pictet North America Advisors SA Increases Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Pictet North America Advisors SA grew its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 28.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 72,154 shares of the company's stock after purchasing an additional 16,030 shares during the period. Pictet North America Advisors SA's holdings in Novo Nordisk A/S were worth $5,010,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Bank of America Corp DE boosted its position in Novo Nordisk A/S by 8.1% during the 4th quarter. Bank of America Corp DE now owns 15,492,384 shares of the company's stock worth $1,332,655,000 after buying an additional 1,165,955 shares during the period. GQG Partners LLC grew its position in shares of Novo Nordisk A/S by 74.7% in the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock valued at $1,117,790,000 after buying an additional 5,556,460 shares during the last quarter. Loomis Sayles & Co. L P increased its stake in shares of Novo Nordisk A/S by 34.2% in the fourth quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock valued at $995,397,000 after buying an additional 2,947,771 shares during the period. Folketrygdfondet raised its position in shares of Novo Nordisk A/S by 0.5% during the fourth quarter. Folketrygdfondet now owns 8,903,938 shares of the company's stock worth $765,917,000 after acquiring an additional 40,313 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Novo Nordisk A/S by 1.5% during the fourth quarter. Renaissance Technologies LLC now owns 8,312,996 shares of the company's stock worth $715,084,000 after acquiring an additional 123,681 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on the company. Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. BNP Paribas began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating on the stock. Wall Street Zen raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Finally, Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Stock Down 0.0%

Shares of Novo Nordisk A/S stock traded down $0.01 during trading on Wednesday, reaching $69.81. 7,902,663 shares of the company traded hands, compared to its average volume of 7,257,370. The firm has a market capitalization of $311.70 billion, a PE ratio of 20.65, a P/E/G ratio of 1.23 and a beta of 0.64. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $143.69. The company has a 50 day moving average price of $69.52 and a 200-day moving average price of $76.51. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The company had revenue of $11.87 billion for the quarter. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.